Skip to main content

Liraglutide vs Retatrutide

Both Liraglutide and Retatrutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

Liraglutide

Evidence A+

Liraglutide (Saxenda / Victoza)

The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.

View full Liraglutide profile →

Retatrutide

Evidence A

Retatrutide (LY3437943)

Triple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.

View full Retatrutide profile →

Side-by-Side

AttributeLiraglutideRetatrutide
Evidence GradeA+A
FDA StatusFDA-approved for weight management (Saxenda) and type 2 diabetes (Victoza)Not FDA-approved — Phase 3 trials (TRIUMPH program) for obesity
Typical Dose0.6–3.0 mg daily (subcutaneous)Trial range: 1–12 mg weekly (subcutaneous)
Clinics Indexed54012
Categoriesweight-loss, metabolicweight-loss, metabolic

Key reported benefits — Liraglutide

  • Weight loss
  • Appetite suppression
  • Glycemic control

Key reported benefits — Retatrutide

  • Highest reported weight loss
  • Triple incretin/glucagon mechanism
  • Metabolic improvement

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons